Effect of surfactant and specific antibody on bacterial proliferation and lung function in experimental pneumococcal pneumonia

International Journal of Infectious Diseases

Volumn 5, Issue 1, 2001, Pages 9-18

  Gan, Xiaozhuang ^a   Jarstrand, Connie ^b   Herting, Egbert ^a   Berggren, Per ^a   Robertson, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Huddinge University   (Sweden)

Author keywords

Pneumonia; Polyclonal antibody; Pulmonary surfactants; Rabbits; Respiratory function; Streptococcus pneumoniae

Indexed keywords

LUNG SURFACTANT EXTRACT; POLYCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; CANNULATION; CELL COUNT; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFECT; LOBAR PNEUMONIA; LUNG COMPLIANCE; LUNG FUNCTION; NEWBORN; NONHUMAN; RABBIT;

EID: 0035044653     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(01)90042-6     Document Type: Article

References (53)

1. Surfactant treatment of full-term newborns with respiratory failure
2. Surfactant replacement therapy for meconium aspiration syndrome
3. Surfactant therapy in full-term neonates with severe respiratory failure
4. Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia
5. Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats
6. Surfactant treatment in experimental Escherichia coli pneumonia
7. Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice
8. Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits
9. Experimental neonatal group B streptococcal pneumonia: Effect of a modified porcine surfactant on bacterial proliferation in ventilated near-term rabbits
10. Preventing pneumococcal disease in children: Recommendations for using pneumococcal vaccine
11. Pneumococcal bacteremia with specific reference to bacteremic pneumococcal pneumonia
12. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia
13. The microbiology of otitis media
14. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: Results of a 1992-93 western Europe and USA collaborative surveillance study
15. Emergence of drug-resistant pneumococcal infections in the United States
16. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations
17. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
18. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine
19. Streptococcus pneumoniae infection and bacteremia in patients with acquired immune deficiency syndrome with report of a pneumococcal vaccine failure
20. Pneumococcal septicemia in children with sickle cell anemia. Changing trend of survival
21. Antibody response to pneumococcal vaccine in patients with multiple myeloma
22. Bacteremias due to Haemophilus influenzae and Streptococcus pneumoniae: Their occurrence and course in children with cancer
23. Pneumococcal infection after human bone-marrow transplantation
24. Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf®) in neonatal respiratory distress syndrome
25. Nonsteroidal anti-inflammatory agents in the therapy for experimental pneumococcal meningitis
26. Application of a new ventilator-multi-plethysmograph system for testing efficacy of surfactant replacement in newborn rabbits
27. Pneumococcus: The first one hundred years
28. The significance of bacterial super-infection in influenza
29. Pneumococcal virulence factors and host immune responses to them
30. Streptococcus pneumoniae
31. Species variation in the mechanism of killing of inhaled pneumococci
32. Role of surfactant free fatty acids in antimicrobial defenses
33. Surfactant improves lung function and morphology in newborn rabbits with meconium aspiration
34. Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimental neonatal group B streptococcal pneumonia
35. Host defense in pulmonary alveoli
36. Maturation of the rabbit alveolar macrophage during animal development. I. Perinatal influx into alveoli and ultrastructural differentiation
37. Inactivation of staphylococci by alveolar macrophages with preliminary observations on the importance of alveolar lining material
38. Effect of alveolar lining material on phagocytic and bactericidal activity of lung macrophages against Staphylococcus aureus
39. Rat lung lavage surfactant enhances bacterial phagocytosis and intracellular killing by alveolar macrophages
40. Phagocytic functions and TNF secretion of human monocytes exposed to natural porcine surfactant (Curosurf)
41. Surfactant therapy of newborn rabbits impairs lung macrophage bactericidal activity
42. The pulmonary surfactant system
43. Surfactant treatment of neonates with respiratory failure and group B streptococcal infections
44. Activity of pulmonary surfactant after blocking the associated proteins SP-A and SP-B
45. Experimental neonatal respiratory failure induced by monoclonal antibodies to the hydrophobic surfactant-associated protein SP-B
46. Antibody to surfactant protein A increases sensitivity of pulmonary surfactant to inactivation by fibrinogen in vivo
47. Natural and vaccine-related immunity to Streptococcus pneumoniae
48. Toxicity of pneumolysin to pulmonary endothelial cells
49. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation
50. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs
51. Influence of pulmonary surfactant on in vitro bactericidal activites of amoxicillin, ceftazidime, and tobramycin
52. Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B streptococcal pneumonia
53. Postscript. Perspectives for the future